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Abstract
Background: The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and
declining efficacy. One potential new target for Chagas’ disease chemotherapy is sterol 14a-demethylase (CYP51), a
cytochrome P450 enzyme involved in biosynthesis of membrane sterols.
Methodology/Principal Finding: In a screening effort targeting Mycobacterium tuberculosis CYP51 (CYP51Mt), we previously
identified the N-[4-pyridyl]-formamide moiety as a building block capable of delivering a variety of chemotypes into the
CYP51 active site. In that work, the binding modes of several second generation compounds carrying this scaffold were
determined by high-resolution co-crystal structures with CYP51Mt. Subsequent assays against the CYP51 orthologue in T.
cruzi, CYP51Tc, demonstrated that two of the compounds tested in the earlier effort bound tightly to this enzyme. Both were
tested in vitro for inhibitory effects against T. cruzi and the related protozoan parasite Trypanosoma brucei, the causative
agent of African sleeping sickness. One of the compounds had potent, selective anti–T. cruzi activity in infected mouse
macrophages. Cure of treated host cells was confirmed by prolonged incubation in the absence of the inhibiting
compound. Discrimination between T. cruzi and T. brucei CYP51 by the inhibitor was largely based on the variability
(phenylalanine versus isoleucine) of a single residue at a critical position in the active site.
Conclusions/Significance: CYP51Mt-based crystal structure analysis revealed that the functional groups of the two tightly
bound compounds are likely to occupy different spaces in the CYP51 active site, suggesting the possibility of combining the
beneficial features of both inhibitors in a third generation of compounds to achieve more potent and selective inhibition of
CYP51Tc.
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Introduction
The drug development pipeline targeting diseases caused by
trypanosome parasites is sparse [1]. Despite significant advances in
its control over the last 15 years [2], Chagas’ disease, caused by the
parasitic protozoan Trypanosoma cruzi [3], remains a major public
health concern in Latin America, with an estimated total of 8
million people infected [4]. Nifurtimox and benznidazole, the two
principal drugs for treatment of Chagas’ disease, were launched in
1967 and 1972 respectively, and suffer from the twin liabilities of
serious side-effects and reduced efficacy in chronic T. cruzi
infections [2]. A potential new target for Chagas’ disease
chemotherapy is sterol 14a-demethylase (CYP51) [5], a cyto-
chrome P450 heme thiolate-containing enzyme which is involved
in biosynthesis of membrane sterols in all biological kingdoms
from bacteria to animals [6]. T. cruzi sterols are similar in
composition to those in fungi, with ergosterol and ergosterol-like
sterols the major membrane components [7]. Clinically employed
antifungal azoles [8,9] inhibit ergosterol biosynthesis in fungi and
are partially effective against Leishmania and Trypanosoma parasites
[10–12]. Azoles block CYP51 activity, resulting in decline of the
normal complement of endogenous sterols and accumulation of
various 14a-methyl sterols with cytostatic or cytoxic consequences
[11]. Aside from the compounds optimized for antifungal therapy,
other CYP51 inhibitors with strong anti-T. cruzi activity have also
been reported [13–15].
Mammalian CYP51 shares relatively modest overall sequence
identity – below 30% – with its fungal and protozoan counterparts,
but within the active site the amino acid residues are far more
conserved. Based upon crystal structures of CYP51 of M.
tuberculosis (CYP51Mt) [16–20], three of the thirteen active site
residues, Y76, F83, and H259 (numbering according to CYP51Mt),
are invariant throughout the cyp51 gene family. Two residues, F78
and F255, are specific to the methylation status of the C-4 atom in
the sterol nucleus [18,21], and amino acid identities of seven other
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positions strongly overlap across phyla [19,20]. Of the thirteen
residues, only one, R96, seems to be phylum-specific. This
similarity confines design of selective CYP51 inhibitors to a
species-specific cavity in the active site defined by the hydrophobic
residues F78, L321, I322, I323, M433, and V434.
To discover novel inhibitors, we previously screened a library of
small synthetic molecules against the CYP51Mt target [19]. The N-
[4-pyridyl]-formamide moiety of the top hit, a-ethyl-N-4-pyridi-
nyl-benzeneacetamide (EPBA), was found to bind unvaryingly in
the CYP51 active site with Y76, H259, and the heme prosthetic
group. The uniformity of interactions with CYP51 suggested that
this scaffold could be used to target a variety of chemotypes to the
active site. To verify this assumption, we determined the binding
modes of second generation compounds containing the N-[4-
pyridyl]-formamide moiety by determining their co-crystal
structures with CYP51Mt. We also spectrally characterized binding
of these compounds to CYP51 of both T. cruzi (CYP51Tc) and the
related protozoan parasite T. brucei, the causative agent of African
sleeping sickness, (CYP51Tb). Two compounds were selected based
on their nanomolar binding affinities toward CYP51Tc and
subsequently tested in vitro for inhibitory effects against both
pathogens. One of the two compounds revealed potent and
selective inhibitory effect against T. cruzi infection in mouse
macrophage cells.
Methods
Preparation of CYP51Mt
CYP51Mt double C37L/C442A and triple C37L/F78L/C442A
mutants were prepared as described elsewhere [19]. The surface
exposed cystein residues C37 and C442 were removed via
replacement with leucine and alanine, respectively, to improve
protein homogeneity and aid crystallization [18]. The functionally
important F78 in the active site was replaced in the triple mutant
by leucine, which invariantly occupies this position in the
mammalian CYP51 isoforms.
Preparation of CYP51Tc
Design of the CYP51Tc expression vector was based on an entity
in the NCBI data bank (ID AY283022 [22]), which was modified
by replacing the first 31 residues upstream of Pro32 with the
fragment MAKKTSSKGKL from the CYP2C3 sequence [23]
(CYP2C3 residues marked in bold) to improve protein solubility,
and by inserting a His6-tag at the C-terminus to facilitate
purification. This coding sequence (kindly provided by M.
Waterman in the form of the pET vector) was subsequently sub-
cloned into pCWori vector [24] between the NdeI and HindIII
restriction sites and in this form used to transform Escherichia coli
strain HMS174(DE3).
Transformants were grown for 5 h at 37uC and 250 rpm
agitation in Terrific Broth medium supplemented with 1 mM
thiamine, 50 mg/ml ampicillin, and trace elements. CYP51Tc
expression was induced by the addition of isopropyl-b-D-
thiogalactopyranoside (IPTG, final concentration 0.2 mM) and
d-aminolevulinic acid, a precursor of heme biosynthesis (final
concentration 1 mM). Following induction, temperature was
decreased to 25uC and agitation to 180 rpm. After 30 hours the
cells were harvested and lysed by sonication. Insoluble material
was removed from crude extract by centrifugation (30 min at
35,000 rpm). The supernatant was subjected to a series of
chromatographic steps, including nickel-nitrilotriacetic acid (Ni-
NTA) agarose (QIAGEN), followed by Q-Sepharose (Amersham
Biosciences) in the flow-through regime, and then by S-Sepharose
(Amersham Biosciences). From the S-Sepharose, protein was
eluted in a 0.2 to 1.0 M NaCl gradient and observed by means of
a 12% SDS-PAGE to be virtually homogeneous. Fractions
containing P450 were combined, concentrated using a Centriprep
concentrating device (Millipore), and stored at 280uC. Twenty
mM Tris-HCl, pH 7.5, 10% glycerol, 0.5 mM EDTA, and 1 mM
DTT were maintained throughout all chromatographic steps.
Spectral characteristics of CYP51Tc are shown in Figure 1A.
Preparation of CYP51Tb
The expression vector for CYP51Tb (ID EAN79583) was
generated using T. brucei genomic DNA and upsteam
GCGCGCATATGGCTCTTGAAGTTGCC and downstream
CGCAAGCTTCTAGTGATGGTGATGGTGATGGTGATGA-
GCAGCTGCCGCCTTCC primers. The underlining denotes an
NdeI restriction cloning site in the upstream primer and the
HindIII restriction cloning site in the downstream primer followed
by the stop codon. The bold sequence in the upstream primer
highlights second codon replaced with alanine to optimize
expression in E. coli cells [24]. The boldface in the downstream
primer indicates the His8 tag. The original genomic DNA
contained internal NdeI site at 345 base pair which was removed
by introducing a silent mutation via the quick-change mutagenesis
protocol (Stratagene). DNA amplification reaction was carried out
as follows: 5 min at 94uC, annealing for 1 min at 55uC, and
extension for 1 min at 72uC, for 30 cycles, followed by extension
for 10 min at 72uC. The purified 1.5 kb PCR product was ligated
into the pCR 2.1 TA cloning vector (Invitrogen). Insert was
subsequently cleaved with NdeI and HindIII and ligated into
pCWori vector digested with the same restriction enzymes and
treated with alkaline phosphatase. The identity of the resulting
vector was confirmed by DNA sequencing.
E. coli HMS174(DE3) strain was co-transformed with this vector
and the pGro7 plasmid (Takara) encoding the E. coli chaperones
GroES and GroEL. Double transformants were selected on agar
plates containing both ampicilin and chloramphenicol. One liter
of Terrific Broth medium supplemented with 1 mM thiamine,
100 mg/ml ampicillin, 40 mg/ml chloramphenicol, and trace
Author Summary
Enzyme sterol 14a-demethylase (CYP51) is a well-
established target for anti-fungal therapy and is a
prospective target for Chagas’ disease therapy. We
previously identified a chemical scaffold capable of
delivering a variety of chemical structures into the
CYP51 active site. In this work the binding modes of
several second generation compounds carrying this
scaffold were determined in high-resolution co-crystal
structures with CYP51 of Mycobacterium tuberculosis.
Subsequent assays against CYP51 in Trypanosoma cruzi,
the agent of Chagas’ disease, demonstrated that two of
the compounds bound tightly to the enzyme. Both were
tested for inhibitory effects against T. cruzi and the
related protozoan parasite Trypanosoma brucei. One of
the compounds had potent, selective anti–T. cruzi activity
in infected mouse macrophages. This compound is
currently being evaluated in animal models of Chagas’
disease. Discrimination between T. cruzi and T. brucei
CYP51 by the inhibitor was largely based on the
variability of a single amino acid residue at a critical
position in the active site. Our work is aimed at rational
design of potent and highly selective CYP51 inhibitors
with potential to become therapeutic drugs. Drug
selectivity to prevent host–pathogen cross-reactivity is
pharmacologically important, because CYP51 is present
in human host.
Rational Design of Anti–T. cruzi CYP51 Inhibitors
www.plosntds.org 2 February 2009 | Volume 3 | Issue 2 | e372
elements was inoculated with 10 ml of overnight culture and
growth continued at 37uC and 250 rpm agitation until OD600
reached 0.3. At that point expression of chaperones was induced
with 0.2% arabinose. Growth continued at 27uC and 180 rpm
until OD reached 0.6. Then CYP51Tb expression was induced by
the addition of isopropyl-b-D-thiogalactopyranoside (IPTG, final
concentration 0.3 mM), and d-aminolevulinic acid (1 mM).
Following induction, temperature was decreased to 15uC. After
48 hours the cells were harvested and lysed by sonication.
Purification was conducted similarly to as described above for
CYP51Tc, with the qualification that S-Sepharose was used in the
flow-through regime, while the protein was bound to and eluted
from the Q-Sepharose column. Spectral characteristics of
CYP51Tb are shown in Figure 1B.
Crystallization, Data Collection, and Determination of
Crystal Structure
Five compounds (Fig. 2), purchased from ChemDiv (San Diego,
California) were used for co-crystallization with the CYP51Mt
C37L/C442A double mutant. Compared to the wild type, this
construct has superior propensity for crystallization. Compound
numbering is according to the order in which they were received
in our laboratory, with number 7 being the first used in the current
work. Ligands were dissolved in Me2SO at #100 mM stock
concentration, and brought to final concentrations ranging from 1
to 5 mM in the crystallization mix, depending on ligand solubility.
Protein concentration was 0.2 mM. A narrow crystallization
screening grid (15–30% PEG 4000, 2–12% isopropanol, 0.1 M
HEPES, pH 7.5), previously devised to obtain CYP51Mt crystals
[16,18,19] was utilized for co-crystallization of complexes by the
vapor diffusion hanging drop method. Four co-crystal forms were
obtained, all diffracted to resolutions between 1.56 to 1.60 A˚.
Diffraction data were collected at 100–110 K at the Southeast
Regional Collaborative Access Team (SER-CAT) 22ID beamline,
Advanced Photon Source, Argonne National Laboratory using
SER-CAT mail-in data collection program (Table 1). The images
were integrated and the intensities merged with the HKL2000
software suite [25]. The structures were determined by molecular
replacement using coordinates of estriol-bound CYP51Mt (Protein
Data Bank ID 1X8V) as a search model. The final atomic models
were obtained after a few iterations of refinement using
REFMAC5 [26] and model-building using the COOT graphics
modeling program [27]. The quality of the structures was assessed
by the program PROCHECK [28]. One residue, A46, was found
in the generously allowed region of the Ramachandran plot in all
structures where, together with the adjacent G47, it enables a
sharp turn between two b strands.
Spectroscopic Binding Assays
Spectroscopic binding assays were performed at room temper-
ature in 1-ml quartz cuvette containing 1 mM or 2 mM CYP51 in
50 mM Tris-HCl, pH 7.5, and 10% glycerol using a Cary UV-
visible scanning spectrophotometer (Varian). Concentration of
CYP51 was determined at 450 nm from the difference spectra
between the carbon monoxide-bound ferrous and water-bound
ferric forms, with an extinction coefficient of 91,000 M21 cm21
[29]. In the first round, compounds dissolved in Me2SO at 10 mM
concentration were added to the 2 mM protein solution in 0.5 ml
aliquots, resulting in concentration increases from 5 mM to 50 mM
in 5 mM increments. The same amounts of Me2SO alone were
added to the protein in the reference cuvette, followed by
recording the difference spectra. In the second round, compounds
with high affinities were diluted to 100 mM by Me2SO and titrated
into 1 mM protein solution in 1 ml aliquots to increase compound
concentration from 0.1 mM to 2 mM in 0.1 mM increments. To
determine the KD, we used the GraphPad PRISM software
(Graphpad Software Inc.) to fit titration data to either rectangular
or quadratic hyperbolas to correct for the bound ligand fraction,
according to the functions DA = (Amax(S/KD+S) or DA = (Amax/
2[E])((KD+[E]+[L])2((KD+[E]+[L])224[E][L])1/2), respectively,
where E is total enzyme and L total ligand concentration, Amax
the maximal absorption shift at saturation, and KD the apparent
dissociation constant for the enzyme-ligand complex.
T. cruzi Assay
Irradiated (1000 rads) J774 mouse macrophages were plated in
12-well tissue culture plates 24 h prior to infection with 105 T. cruzi
Y strain trypomastigotes for 2 h at 37uC. Cultures were
maintained in RPMI-1640 medium with 5% heat-inactivated
fetal calf serum and 5% CO2 with the addition of 10 mM
compound 8 or 10. Untreated controls, controls treated with the
inhibitor K11777 (10 mM) [30,31], and uninfected macrophage
controls were also included. All cultures were in triplicate and
medium was replaced every 48 h. Treatment with CYP51
inhibitors continued for up to 27 days. Subsequently, treated
cultures were maintained without inhibitor for an additional 13–
Figure 1. Spectral characteristics of CYP51Tc (A) and CYP51Tb
(B). Main panel shows the absolute protein spectrum, while insert
shows CO-bound reduced difference spectrum.
doi:10.1371/journal.pntd.0000372.g001
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15 days to confirm inhibitor effectiveness and cure of infected cells.
Cultures were monitored daily by contrast phase microscopy to
determine presence of T. cruzi infected cells and free infectious
trypomastigotes (Table 2).
IC50
To determine IC50, mouse J774 macrophages were irradiated
(1000 rads) to deter growth and plated onto 12-well tissue culture
plates. Cells were infected with 105 tissue culture trypomastigotes
of the Y strain of T. cruzi for 2 h at 37uC, as described above. Next,
medium was replaced with the addition of compound 10 at 0,
1 nM, 10 nM, 100 nM, 500 nM, 1 mM, 5 mM, and 10 mM; these
cultures were incubated for 52 h at 37uC. Controls with 10 mM
K11777 and 10 mM compound 8 were also included. All
treatments were performed in triplicate to ensure statistical
validity. Cultures were then fixed in 4% paraformaldehyde in
PBS for 2 h at room temperature and stained with DAPI (10 nM)
in PBS. One hundred cells and their intracellular parasites were
quantified as previously described to estimate the mean number of
parasites/cell [32]. Mean P/cell data were plotted against
compound concentration to estimate the IC50.
Mammalian Cell Toxicity Assay
Toxicity was evaluated in bovine muscle cells (BESM), mouse
J774 macrophages, and human Huh7 hepatocytes against
compound 10 at 10 mM, 50 mM and 100 mM concentrations.
After 48 h in culture at 37uC, cells were stained with 10% Tripan
Blue and the number of live versus dead cells was quantified
(Table 3).
T. brucei Assay
Trypanosomes were grown in complete HMI-9 medium
containing 10% FBS, 10% Serum Plus medium (Sigma Inc. St.
Louis Mo. USA) and 16 penicillin/streptomycin. Trypanosomes
were diluted to 1.06105/ml in complete HMI-9 medium. Diluted
trypanosomes were aliquoted in Greiner sterile 96-well flat white
opaque culture plates using a WellMate cell dispenser (Matrix
Tech., Hudson, NH, USA). Compounds 8 and 10 were serially
diluted in Me2SO. Trypanosomes were incubated with the
compounds for 48 h at 37uC with 5% CO2 before monitoring
viability. Trypanosomes were then lysed in the wells by adding
50 ml of CellTiter-GloTM (Promega Inc., Madison, WI, USA).
Lysed trypanosomes were placed on an orbital shaker at room
temperature for 2 min. The resulting ATP-bioluminescence of the
trypanosomes in the 96-well plates was measured at room
temperature using an Analyst HT plate reader (Molecular
Devices, Sunnyvale, CA, USA).
Results
Crystal Structures of CYP51Mt-Inhibitor Complexes
Co-crystals were obtained for compounds 8, 9 and 11.
Compound 10 failed to generate any crystals with CYP51Mt.
Compound 7 was not found in the CYP51Mt active site in the
Figure 2. Chemical structures and binding affinities of compounds. 1Compounds are identified by the numbers in the ChemDiv, Inc.,
product library catalog.
doi:10.1371/journal.pntd.0000372.g002
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crystal, which is consistent with lack of spectrally detectable
binding (Fig. 2). Compounds 8 (3-{[(4-methylphenyl)sulfonyl]a-
mino}propylpyridin-4-ylcarbamate), 9 (cis-4-methyl-N-[(1S)-3-
(methylsulfanyl)-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecar-
boxamide), and 11 (N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)-
propyl]cyclohexanecarboxamide), were observed bound in the
CYP51Mt active site as predicted, through the coordination of the
heme iron via a lone pair of aromatic nitrogen electrons of the N-
[4-pyridyl]-formamide moiety (highlighted in gray in Fig. 2) and
interactions with the invariant residues Y76 and H259 (Fig. 3).
Functional groups other than the N-[4-pyridyl]-formamide moiety
in compounds 9 and 11 either were accommodated in the species-
specific cavity or else protruded through the opening of the active
site toward bulk solvent. H259 hydrogen-bonded to the carbonyl
oxygen in both compounds, while interactions with Y76 were
mediated by two similarly positioned water molecules (Figs. 3A
and 3B). The residual Fo-Fc electron density map suggested two
alternative conformations for compounds 11 and 9, designated by
pink and cyan respectively in Figures 4A and 4B. In the CYP51Mt-
compound 11 complex, the cyclohexane ring protruded toward
the bulk solvent (Fig. 3A), barely interacting with the protein in
two alternative conformations (Fig. 4A). Together with the limited
interactions of the isopropyl moiety, this lack of contact explains
the low binding affinity of 11. In the CYP51Mt-compound 9
complex, the methylcyclohexane moiety protruded toward bulk
solvent, while the methylsulfanyl group loosely bound in the
species-specific cavity (Fig. 3B) in two alternative conformations
(Fig. 4B). The side chain of M433 also adopted two alternative
conformations. In both complexes, a portion of the BC-region was
disordered and missing from the electron density map. Although
racemic mixtures were used for co-crystallization, only one
enantiomer of each compound was found in the active site.
A different binding mode was revealed for compound 8. Its
flexible backbone allowed it to fold head-to-tail over the heme
plane to bring the methylphenylsulfonamide group into intramo-
lecular stacking interactions with the pyridinyl moiety and also
with the heme macrocycle (Fig. 3C, 4C). Folding minimized the
nonpolar surface of compound 8 by exposing the sulfonamide
group to interactions with Q72, K97, and the heme propionate
side chain. The hydrophobic side chain of K97 aligned along the
methylphenyl moiety. A similar folding of the benzothiadiazolsul-
fonamide group has been observed in previous work for 2-[(2,1,3-
benzothiadiazol-4-sulfonamide]-2-phenyl-N-pyridin-4-acetamide
(BSPPA) [19]. Mutually stabilizing protein-ligand interactions
involving the BC-loop residues including F78 result in increased
binding affinity of the CYP51Mt-compound 8 complex and in
unambiguous electron density both for compound 8 (Fig. 3C) and
for the entire BC-region. In the CYP51Mt-compound 8 complex,
H259 directly H-bound to the amide nitrogen of compound 8,
whereas Y76 interacted hydrophobically with the compound’s
flexible backbone (Fig. 3C).
Binding Affinities of CYP51 Ligands
Binding affinities of all five compounds were examined against
both wild type and a ‘humanized’ F78L mutant form of CYP51Mt,
CYP51Tc, and CYP51Tb using spectroscopic assays (Fig. 5). These
assays utilize the property of P450 enzymes to shift the ferric heme
iron Soret band following replacement of a weak ligand, the water
molecule, with a stronger one, the nitrogen-containing aromatic
pyridinyl group (Fig. 5A). All compounds had markedly reduced
or no binding affinity toward CYP51Mt, compared to the parental
EPBA (Fig. 2). No binding was observed for compound 7, while
Table 1. Crystallographic data and statistics.
Compound # Compound 8 Compound 9 Compound 11
ChemDiv # 4596-0233 C155-0065 C155-0337
PDB ID 2W0B 2W09 2W0A
Data collection
Wavelength, A˚ 1.0000 1.0000 1.0000
Resolution, A˚ 1.56 1.57 1.60
Unique reflections 63021 59811 53704
Redundancya 5.5 (4.7) 5.4 (3.4) 5.1 (3.9)
Completness, % 99.5 (99.1) 95.8 (79.4) 93.8 (77.7)
Space group P212121 P212121 P212121
Cell dimensions (a, b, c), A˚ 46.7, 84.8, 110.3 46.4, 85.1, 110.9 44.7, 85.7, 110.9
Molecules in asymmetric
unit
1 1 1
Solvent content, % 40 40 40
Rsym
b, % 5.2 (29.7) 7.7 (32.8) 7.0 (32.2)
I/s 32.1 (4.3) 45.5 (4.4) 32.5 (3.4)
Refinement
Reflections used in
refinement
62962 59743 53638
Rcryst (Rfree)
c, % 16.4/20.1 18.8/22.2 18.9/23.2
No. of atoms 3989 3753 3726
Protein 3542 3409 3376
Heme 43 43 43
Substrate 24 24 22
Water 380 277 285
Wilson plot B-values, A˚2 15.2 22.6 18.7
Mean B-factor, A˚2 14.6 25.5 20.3
Protein 14.0 24.9 19.7
Heme 9.6 22.6 21.0
Substrate 14.9 29.0 21.0
Water 22.8 32.6 27.8
r.m.s. deviations
Bond length, A˚ 0.010 0.013 0.013
Bond angles, u 1.3 1.4 1.4
Ramachandran (%)d 91.9/7.9/0.3 91.7/8.0/0.3 91.5/8.2/0.3
aNumbers in parentheses correspond to the highest resolution shell.
bRsym = .S|Ii2ÆIæ|/SIi, where Ii is the intensity of the i
th observation, and ÆIæ is the
mean intensity of reflection.
cRcryst =SIFo|2|FcI/ .S|Fo|, calculated with the working reflection set. Rfree is
the same as Rcryst but calculated with the reserved reflection set.
dProgram PROCHECK [28], portions of the protein residues in most favored/
additional allowed/generously allowed regions.
doi:10.1371/journal.pntd.0000372.t001
Table 2. T. cruzi infection in vitro.
Treatment Host cell survival T. cruzi development
Untreated control 5 days 5 days
Compound 8 (10 mM) 5 days 5 days
Compound 10 (10 mM) 40 days No
K11777 control 40 days No
doi:10.1371/journal.pntd.0000372.t002
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the KD for compound 11 exceeded 100 mM, indicating weak
binding.
However, the binding affinity of all compounds examined,
including compound 7, was significantly higher to CYP51Tc than
to CYP51Mt. Remarkably, the binding affinities of compounds 8 and
10 to CYP51Tc were 300- and at least 500-fold respectively higher,
equaling or exceeding that of the antifungal CYP51 inhibitor
fluconazole, which was used as a reference (Fig. 5B, C). A KD of at
least 40 nM was estimated for compound 10 by spectral assays, with
the binding curve reaching a plateau at about a 1:1 protein to ligand
ratio. This value strongly suggests that the KD must be notably
higher, although further dilution of protein in an attempt to obtain a
more accurate value significantly decreased the quality of the spectra
and this effort was thus abandoned. The IC50 of,1 nM for T. cruzi
intracellular growth inhibition, determined for compound 10 as
described below, may better reflect true KD value. Compounds 8
and 10, which had highest binding affinity to CYP51Tc, were
spectrally silent toward CYP51Tb, indicating no binding in the active
site (Fig. 2). As expected, CYP51Tb had nanomolar affinity for
fluconazole (Fig. 5D), but again, the plateau was reached at a 1:1
protein to inhibitor ratio, so the binding constant could not be
determined more accurately. Compound 9 bound both CYP51Tc
and CYP51Tb with the same affinity.
The KD values for compounds 8 and 10 slightly decreased for
the F78L CYP51Mt mutant compared to the wild type, while the
KD values for the other compounds increased (Fig. 2).
Inhibitory Effects against T. cruzi
With submicromolar affinities toward CYP51Tc of 160 nM and
,40 nM respectively, compounds 8 and 10 were examined in vitro
for inhibitory effects against both T. cruzi and T. brucei. In a mouse
macrophage assay, T. cruzi completed its intracellular development
in 5 days in untreated controls, resulting in death of host
macrophages and abundant trypomastigotes in culture superna-
tant (Table 2). As anticipated, the control compound K11777 [30]
cured T. cruzi infection. No parasites survived a treatment regime
of 27 days with compound 10. Cure of host cells was confirmed by
incubation of the cultures for an additional 15 days in the absence
of inhibitor. In contrast, and similarly to untreated controls, T.
cruzi completed its development in 5 days in cultures treated with
compound 8.
An IC50 of,1 nM concentration for compound 10 (Fig. 6) was
estimated for T. cruzi intracellular amastigotes. T. cruzi developed
well intracellularly in untreated macrophages with a final mean
number of 3.5760.5 P/cell (0% inhibition). As determined
previously, 10 mM compound 10 was deleterious for T. cruzi,
with a mean of 0.2560.01 P/cell (100% growth inhibition). Ten
mM of control compound K11777 was also parasiticidal for T.
cruzi with a mean of 0.2560.01 P/cell (IC100) [30], while
compound 8 was not parasiticidal at this concentration with a
mean of 1.2260.1 P/cell (data not shown).
Toxicity for mammalian cells was addressed by treating the
three different cell types with increasing concentrations of
compound 10 (Table 3). No toxicity was observed at 10 mM
compound 10, while 50 mM was mildly toxic for muscle cells. One
hundred mM compound 10 was toxic for all mammalian cells
tested, especially muscle cells.
Consistent with the spectral binding assays, neither compound 8
nor 10 had any inhibitory effects against cultured T. brucei even at
the highest tested concentration of 10 mM.
Table 3. Toxicity in mammalian cells.
Treatment Mean Live Cells6SD
BESM (bovine) Macrophages (mouse) Hepatocytes (human)
Untreated control 8965 97.560.8 92.560.8
Compound 10 (10 mM) 88.560.5 9660.1 9461
Compound 10 (50 mM) 62.560.8 9160.1 8363
Compound 10 (100 mM) 1061 1560.5 5361
doi:10.1371/journal.pntd.0000372.t003
Figure 3. Overall view of compound binding in the active site. Compounds 11 (A), 9 (B), and 8 (C) (highlighted in pink) bound in the active
site of CYP51Mt are shown looking in from the active site opening. For clarity only one conformation of each compound is shown. Protein is
represented by the semitransparent accessible surface (gray). The ordered BC-loop obstructs the view in the CYP51Mt-8 complex in (C). The invariable
elements of the CYP51 active site, Y76, H259 (yellow), and heme (green), are in a stick mode. Water molecules are shown as red spheres. Oxygen atoms
are red, nitrogen blue, sulfur yellow. Images were generated using the VMD program [35].
doi:10.1371/journal.pntd.0000372.g003
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Protein Data Bank Accession Numbers
The atomic coordinates and structure factors determined in this
study (Protein Data Bank IDs 2W09, 2W0A, and 2W0B) have
been deposited in the Protein Data Bank, Research Collaboratory
for Structural Bioinformatics, Rutgers University, New Brunswick,
NJ (http://www.rcsb.org/).
Discussion
We explored sterol 14a-demethylase (CYP51) as a potential
target for trypanosomiasis chemotherapy by probing CYP51Mt,
CYP51Tc, and CYP51Tc with second generation compounds that
contain a universal building block, the N-[4-pyridyl]-formamide
moiety, which is capable of delivering small molecule compounds
to the CYP51 active site. The affinities of the N-[4-pyridyl]-
formamide-derivative compounds that we tested against CYP51Mt
were lower than that of EPBA (Fig. 2), from which the formamide
building block was derived. Affinities of all compounds examined
were much higher toward CYP51Tc than to CYP51Mt. Strikingly
large increases in binding affinities – 300 and 500 fold – were
observed for compounds 8 and 10. Although compound 10 did
not produce crystals with CYP51Mt, based on the binding modes
Figure 4. Stereo view of compounds in the active site. Compounds 11 (A), 9 (B), and 8 (C) are shown surrounded by the CYP51 active site
residues. The fragments of the electron density 2Fo-Fc map (gray mesh) are cut at 1.2 s. Different conformers in (A) and (B) are highlighted in pink
and cyan. Images were generated using PYMOL [36].
doi:10.1371/journal.pntd.0000372.g004
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Figure 5. Spectroscopic binding of compounds. (A) Type II spectral responses of CYP51Tc to increasing concentrations of compound 10. The
concentration dependence of compound 10, fluconazole (B), and compound 8 (C) binding were deduced from the difference absorption changes
obtained from the titration of CYP51Tc with increasing concentrations of the inhibitor. The concentration dependence of fluconazole (D) was
deduced from the difference absorption changes obtained from the titration of CYP51Tb.
doi:10.1371/journal.pntd.0000372.g005
Figure 6. Inhibition of T. cruzi intracellular amastigotes by compound 10. T. cruzi intracellular multiplication was evaluated at 52 hr of
incubation at several concentrations of the inhibitor by determining the number of parasites/cell. Intracellular parasites were counted per one
hundred cells to estimate a mean number of parasites per cell. Approximation of concentration dependence of mean P/cell6SD data with a smooth
curve highlights the 50% drop in parasite count at ,1 nM compound 10. SD did not exceed 14% of the mean.
doi:10.1371/journal.pntd.0000372.g006
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of compounds 9 and 11, we reason that the methylcyclohex-
anecarboxamide moiety of compound 10 protrudes toward the
BC-loop, suggesting that the indole ring binds in the species-
specific cavity, including the space occupied in CYP51Mt by the
F78 aromatic ring, which is absent from CYP51Tc but present in
CYP51Tb and CYP51Mt. Consistent with this hypothesis, com-
pound 10 selectively bound CYP51Tc, inhibited T. cruzi growth
with the IC50 value close to the KD estimated in the spectral
binding assays, and cured mouse macrophages infected with T.
cruzi Y strain at 10 mM concentration without harming them.
In contrast, compound 10 failed to bind CYP51Tb despite the
identity of 12 of the 13 active site substrate binding residues, and
83% overall sequence identity between T. cruzi and T. brucei
CYP51 orthologues. This result is a striking indication of the
sensitivity of CYP51 to alterations of the topography of its active
site at position 78. The difference in position 78 is of functional
importance, because phenylalanine at this site is strictly specific to
protozoa and plant species metabolizing 4a-methylated sterols
[18]. Interestingly, T. cruzi is the only protozoan where the
corresponding position (position 105 according to T. cruzi
numbering) is occupied by isoleucine. Consistent with this
observation, CYP51Tc is catalytically more closely related to its
fungal and animal orthologues, preferentially converting 4a,b-
dimethylated sterol substrates [21], whereas T. brucei CYP51 is
strictly specific to 4a-methylated obtusifoliol and norlanosterol
[33]. The proteobacterium Methylococcus capsulatus, known to
synthesize sterols from squalene [34], is the only other known
organism having isoleucine in the CYP51 position corresponding
to F78. Not surprising, compound 10 was inactive against T. brucei
in inhibitory assays in vitro.
In humans and animals metabolizing 4a,b-dimethylated 24,25-
dihydrolanosterol, position 78 is always occupied by leucine.
Therefore, the F78L substitution in the CYP51Mt binding site was
examined and found to slightly increase binding affinities toward
compounds 8 and 10, as opposed to the rest of the compounds
whose binding affinities decreased (Fig. 2). Although a single
amino acid substitution does not by any means convert bacterial
protein into its mammalian counterpart, this finding is consistent
with lack of toxicity in mammalian cells at inhibitory concentra-
tions, and supports the possibility of rational design of highly
selective anti-protozoan CYP51 inhibitors. The latter is of
particular pharmacological importance as far as host-pathogen
cross-reactivity is concerned, since CYP51 is present in human
host.
The increased binding affinities toward CYP51Tc of all the
compounds we tested may indicate more extensive involvement of
the BC-loop and C helix in protein-inhibitor interactions in
CYP51Tc than in CYP51Mt. Assuming that compound 8 binds
CYP51Tc in a similarly compact donut-like shape that fills the
space adjacent to the porphyrin ring, its 300-fold increase in
binding affinity could be achieved solely by stabilization of the BC-
region of CYP51Tc without engaging the species-specific cavity.
This possibility opens the door to a rational design effort in which
the beneficial features of both compounds 8 and 10 would be
combined to yield third generation compounds that would more
potently and selectively inhibit CYP51Tc. Toward this end
compound 10 is currently being evaluated in animal models of
Chagas’ disease.
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